The Oregonian shares insight on the new Multnomah County deflection center’s first week of operation, highlighting OHSU’s efforts to develop a bed tracker for hospitals and recovery organizations across the state.

Pangea Biomed announced the beginning of a pilot collaboration with the OHSU Knight Cancer Institute to explore the ability to predict personalized cancer treatment response using data processed through the Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Clinical Trials Program. Gordon Mills, M.D., Ph.D., says: “Through our pilot collaboration with Pangea, our goal is to identify therapies that can overcome cancer drug resistance, paving the way for more effective treatments tailored to each individual patient.”

OHSU researchers Amy Moran, Ph.D., Claymore Kills First, Pharm.D., and Laura Heiser, Ph.D., participate in an expert panel to discuss “next-generation cancer detection methods, therapies and treatments, access to care, and the impact of funding from the Kuni Foundation.” Heiser says one of the most challenging issues in cancer research today is setting up teams of individuals all focused on tackling a key problem in cancer, which is a complex disease. “There isn’t a single approach that is going to give us all the answers. So thinking about different approaches and then identifying not just the expertise needed, but the key individuals who can work together,” she says.

An OHSU study leveraging a database of millions of veterans nationwide reveals a possible connection between hearing loss and Parkinson’s disease. Lee Neilson, M.D., says, “We still have much to learn about how hearing loss contributes to Parkinson’s and how hearing aids might work to lower one’s risk. Considering there are few downsides to getting screened and fitted for a hearing aid, we would encourage everyone to do it.”

Six young patients revealed their personally designed Nike sneakers on Friday, Oct. 18, raising more than $1.5 million to support life-saving care and leading-edge research at Doernbecher Children’s Hospital. Dana Braner, M.D., says, “As we celebrate Doernbecher Freestyle’s 20th anniversary, we also reflect on two extraordinary decades of hope and healing. Each year I am amazed by the strength of these kids, as well as the incredible generosity of our community. This program allows us to support families in need and provide specialized care unavailable anywhere else in the region, and we’re so grateful to everyone who makes this possible.”

Leah Werner, M.D., is quoted in a Water Quality Research Foundation press release highlighting efforts to educate and help people access cleaner drinking water: "Lead exposure poses serious health risks, particularly for children and pregnant women. It's crucial for individuals to understand these dangers and take proactive steps to protect their families. Utilizing effective filtration systems can significantly reduce lead levels in drinking water, ensuring safer, cleaner water for households and schools everywhere."

A new study suggests a low-carbohydrate diet may help adults with type 2 diabetes gain better blood sugar control and make it possible to decrease diabetes medication. Leah Wilson, M.D., says, including African Americans with European Americans in the study sheds light on how diabetes affects different groups and "there can be improvements in some parameters of beta-cell function with a very low carbohydrate diet even in the absence of weight loss."

Kristina Haley, M.D., joins The Puberty Podcast to discuss a range of bleeding issues, including heavy periods, clotting and anemia.

Modeling data suggest the decision to grant personhood status to embryos in Alabama was associated with hundreds fewer IVF cycles and live births and poorer quality of life. David Monroe, M.D., says. “The ruling immediately had consequences for women and providers in that state … . When looking at policies, we should address IVF access in ways that improve health.”

Scientists share updates on a proof-of-concept of gene editing for transthyretin (ATTR) amyloidosis with cardiomyopathy ATTR-CM. Ahmad Masri, M.D., says, “The majority of the patients, if not all of them, as far as we've seen from the data, had TTR suppression or knockdown or silencing by more than 90% and that's with a single administration, regardless of the dose that was chosen. Overall, from the data presented it seems to [be] a safe strategy.”